Novartis AG (NYSE:NVS) Shares Sold by Lantz Financial LLC

Lantz Financial LLC trimmed its position in shares of Novartis AG (NYSE:NVS) by 5.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,478 shares of the company’s stock after selling 384 shares during the period. Lantz Financial LLC’s holdings in Novartis were worth $630,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Cyndeo Wealth Partners LLC raised its holdings in shares of Novartis by 2.7% in the 4th quarter. Cyndeo Wealth Partners LLC now owns 4,725 shares of the company’s stock worth $460,000 after purchasing an additional 123 shares during the period. Geneos Wealth Management Inc. increased its position in Novartis by 3.6% during the 4th quarter. Geneos Wealth Management Inc. now owns 30,156 shares of the company’s stock worth $2,934,000 after purchasing an additional 1,058 shares in the last quarter. apricus wealth LLC raised its holdings in Novartis by 2.8% in the fourth quarter. apricus wealth LLC now owns 21,813 shares of the company’s stock valued at $2,123,000 after buying an additional 600 shares during the period. DGS Capital Management LLC lifted its position in Novartis by 18.0% during the fourth quarter. DGS Capital Management LLC now owns 12,601 shares of the company’s stock valued at $1,226,000 after buying an additional 1,918 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. grew its stake in Novartis by 10.0% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 3,763 shares of the company’s stock worth $366,000 after buying an additional 343 shares during the period. 13.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. BMO Capital Markets lifted their target price on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. Erste Group Bank restated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Finally, HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Two research analysts have rated the stock with a sell rating and six have assigned a hold rating to the stock. According to MarketBeat, Novartis presently has a consensus rating of “Hold” and an average price target of $123.38.

Novartis Stock Performance

Shares of NVS opened at $99.93 on Friday. The firm has a market cap of $204.25 billion, a price-to-earnings ratio of 11.61, a PEG ratio of 1.42 and a beta of 0.57. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. The business’s 50 day moving average is $100.09 and its two-hundred day moving average is $108.69. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The business had revenue of $12.82 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter last year, the company posted $1.74 earnings per share. Analysts forecast that Novartis AG will post 7.62 EPS for the current fiscal year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.